ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Thromboelastography in Liver Transplantation: A Target Group

A. Mohamed1, T. Kitajima1, J. Cui1, S. Angappan2, K. Delvecchio1, T. Shamaa1, T. Ivanics3, S. Shimada1, M. Rizzari1, K. Collins1, A. Yoshida1, M. Abouljoud1, J. El-Bashir2, S. Nagai1

1Henry Ford Transplant Institute, Detroit, MI, 2Henry Ford Hospital, Detroit, MI, 3Surgery, Henry Ford Transplant Institute, Detroit, MI

Meeting: 2022 American Transplant Congress

Abstract number: 1510

Keywords: Liver transplantation, Outcome, Resource utilization

Topic: Clinical Science » Organ Inclusive » 71 - Surgical Issues (Open, Minimally Invasive):All Organs

Session Information

Session Name: Surgical Issues (Open, Minimally Invasive): All Organs

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Liver dysfunction results in derangement of hemostasis and thrombosis. Thromboelastography (TEG) has emerged as a tool to guide resuscitative efforts. However, its utilization and application in liver transplant (LT) surgery has not been established. We aim to identify possible effects of TEG utilization on product use, post-operative complications, and length of stay (LOS).

*Methods: Adult patients who received LT between 2014 and 2020 were retrospectively reviewed. Those patients who underwent living donor, simultaneous or multi-organ transplants, re-transplants, and recipients <18 years of age were excluded. Possible impact of TEG implementation on blood product use, pressor requirements, post-operative complications, and cost to patients was analyzed. A subgroup analysis was done based on INR at transplant. The median, 75th, and 90th percentile of INR at transplant were used as cut-off values and patients were classified into four categories: no coagulopathy (INR ≤1.6), mild (INR 1.7-2.2), moderate (INR 2.3-2.8), and severe coagulopathy (INR >2.8) (Figure 1).

*Results: A total of 451 patients met inclusion criteria and were separated into TEG (n=207) vs non-TEG (n=244) groups. Background characteristics between these two groups were comparable. Overall, no significant differences between transfusion requirements and blood loss were found between the two groups. In the subgroup analysis, there was a significant decrease in product use in the TEG group with moderate coagulopathy, compared to the non-TEG group (Table 1). When looking at complications, there was a significantly higher proportion of hospital readmissions and biliary complications in non-TEG patients (Table 2). Of the biliary complications, non-TEG patients developed more bile leaks. Although there is not a statistically significant difference in hospital length of stay, the median length of stay for non-TEG patients was 9 days whereas that of TEG patients was 8 days (Table 2).

*Conclusions: TEG guided hemostasis and resuscitation in LT resulted in a decrease in product usage in patients with moderate coagulopathy (INR 2.3-2.8). Refined product use may also contribute to decreased incidence of bile leaks.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Mohamed A, Kitajima T, Cui J, Angappan S, Delvecchio K, Shamaa T, Ivanics T, Shimada S, Rizzari M, Collins K, Yoshida A, Abouljoud M, El-Bashir J, Nagai S. Thromboelastography in Liver Transplantation: A Target Group [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/thromboelastography-in-liver-transplantation-a-target-group/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences